Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Twist Bioscience Corp (TWST)

Twist Bioscience chosen as evaluator for Anthropic AI protein design campaign

Neutral Impact 2 of 5 product/contract Written later

Twist Bioscience disclosed that Anthropic, PBC published a blog post on August 18, 2026, saying it had received data from a protein design campaign against 15 targets using Claude Opus 4.8 and Mythos Preview. Anthropic said it chose Twist as one of its independent evaluators to rapidly produce these AI-designed proteins at scale and test them for binding. The filing gives no financial terms, revenue figures, or contract value, so its effect on shareholders is not quantified.

Key points

  • Anthropic published a blog post on August 18, 2026 describing a multi-arm protein design campaign against 15 targets.
  • The campaign used Claude Opus 4.8 and Mythos Preview.
  • Anthropic named Twist Bioscience as one of its independent evaluators to produce and test AI-designed proteins for binding.
  • The filing is furnished under Item 7.01 and gives no financial figures for the arrangement.

The filing

CompanyTwist Bioscience Corp (TWST)
Form8-K, current report
Filed with the SECAug 18, 2026, 6:15 PM ET
Accession number0001581280-26-000050

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 18, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.